Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16872693 | 0.95 | EGFR (0.45) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL877561 | 0.93 | EGFR (0.44) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL877114 | 0.91 | ABCG2 (0.45) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL877185 | 0.90 | EGFR (0.44) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL876736 | 0.90 | ABCG2 (0.51) | ABCG2ABCB1 | |
| SCHEMBL882886 | 0.89 | EGFR (0.44) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL10220824 | 0.89 | EGFR (0.44) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL877430 | 0.89 | ERBB2 (0.47) | EGFRITKROCK2ABCG2ABCB1 | |
| SCHEMBL3799508 | 0.88 | ROCK2 (0.51) | EGFRITKROCK2ERBB2CHEK2 | |
| SCHEMBL3794082 | 0.87 | ABCG2 (0.53) | EGFRITKROCK2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20120202793-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | EGFR 3187/4885ITK 4592/4885ROCK2 1/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | EGFR 3187/4885ITK 4592/4885ROCK2 1/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | EGFR 3187/4885ITK 4592/4885ROCK2 1/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | EGFR 3187/4885ITK 4592/4885ROCK2 1/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | EGFR 3187/4885ITK 4592/4885ROCK2 1/4885 |
| US-20120202793-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | EGFR 2240/4885ITK 2797/4885ROCK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.